Targeting death receptors in bladder, prostate and renal cancer

Journal of Urology

Volumn 175, Issue 2, 2006, Pages 432-438

  O'Kane, Hugh F ^a   Watson, Chris J ^a   Johnston, Samuel R ^a   Petak, Istvan ^b   William, R ^c   Watson, G ^c   Williamson, Kate E ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Apoptosis; Bladder neoplasms; Immune system; Kidney neoplasms; Prostate neoplasms

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BCG VACCINE; CASPASE; DEATH RECEPTOR; FAS ANTIGEN; LIGAND; RECOMBINANT PROTEIN; RECOMBINANT TUMOR NECROSIS FACTOR; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CARCINOGENESIS; CELL ACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; IMMUNE SYSTEM; KIDNEY CANCER; METHYLATION; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RECEPTOR GENE; REVIEW; RNA SPLICING; TUMOR CELL;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; HUMANS; KIDNEY NEOPLASMS; MALE; MEMBRANE GLYCOPROTEINS; PROSTATIC NEOPLASMS; RECEPTORS, CELL SURFACE; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 6B; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA; URINARY BLADDER NEOPLASMS;

EID: 30344455043     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)00160-6     Document Type: Review

References (60)

1. T. Sejima, T. Isoyama, I. Miyagawa Alteration of apoptotic regulatory molecules expression during carcinogenesis and tumor progression of renal cell carcinoma Int J Urol 10 2003 476
2. S. Maas, U. Warskulat, C. Steinhoff, W. Mueller, M.O. Grimm, W.A. Schulz Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status Urology 63 2004 392
3. H.L. Maecker, C. Koumenis, A.J. Giaccia p53 promotes selection for Fas-mediated apoptotic resistance Cancer Res 60 2000 4638
4. K. Shimada, M. Nakamura, E. Ishida, M. Kishi, N. Konishi Androgen and the blocking of radiation-induced sensitization to Fas-mediated apoptosis through c-jun induction in prostate cancer cells Int J Radiat Biol 79 2003 451
5. I. Petak, D.M. Tillman, F.G. Harwood, R. Mihalik, J.A. Houghton Fas-dependent and -independent mechanisms of cell death following DNA damage in human colon carcinoma cells Cancer Res 60 2000 2643
6. S. Shankar, T.R. Singh, R.K. Srivastava Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo intracellular mechanisms Prostate 61 2004 35
7. C. Choi, M.H. Kim, S.W. Juhng, B.R. Oh Loss of heterozygosity at chromosome segments 8p22 and 8p11.2-21.1 in transitional-cell carcinoma of the urinary bladder Int J Cancer 86 2000 501
8. G.S. Bova, D. MacGrogan, A. Levy, S.S. Pin, R. Bookstein, W.B. Isaacs Physical mapping of chromosome 8p22 markers and their homozygous deletion in a metastatic prostate cancer Genomics 35 1996 46
9. M.A. Eid, R.W. Lewis, A.B. Abdel-Mageed, M.V. Kumar Reduced response of prostate cancer cells to TRAIL is modulated by NFkappaB-mediated inhibition of caspases and Bid activation Int J Oncol 21 2002 111
10. H. Wang, K. Song, T.L. Sponseller, D. Danielpour Novel function of androgen receptor-associated protein 55/Hic-5 as a negative regulator of Smad3 signaling J Biol Chem 280 2005 5154
11. I. Behrmann, H. Walczak, P.H. Krammer Structure of the human APO-1 gene Eur J Immunol 24 1994 3057
12. D. Munsch, R. Watanabe-Fukunaga, J.C. Bourdon, S. Nagata, E. May, E. Yonish-Rouach Human and mouse Fas (APO-1/CD95) death receptor genes each contain a p53-responsive element that is activated by p53 mutants unable to induce apoptosis J Biol Chem 275 2000 3867
13. I. Petak, R.P. Danam, D.M. Tillman, R. Vernes, S.R. Howell, L. Berczi Hypermethylation of the gene promoter and enhancer region can regulate Fas expression and sensitivity in colon carcinoma Cell Death Differ 10 2003 211
14. S. Santourlidis, U. Warskulat, A.R. Florl, S. Maas, T. Pulte, J. Fischer Hypermethylation of the tumor necrosis factor receptor superfamily 6 (APT1, Fas, CD95/Apo-1) gene promoter at rel/nuclear factor kappaB sites in prostatic carcinoma Mol Carcinog 32 2001 36
15. N. Shivapurkar, S. Toyooka, K.O. Toyooka, J. Reddy, K. Miyajima, M. Suzuki Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types Int J Cancer 109 2004 786
16. S.H. Lee, M.S. Shin, W.S. Park, S.Y. Kim, S.M. Dong, J.H. Pi Alterations of Fas (APO-1/CD95) gene in transitional cell carcinomas of urinary bladder Cancer Res 59 1999 3068
17. H. Takayama, T. Takakuwa, Y. Tsujimoto, N. Nonomura, A. Okuyama, K. Aozasa Analysis of Fas gene mutations on laser capture microdissected specimens from renal cell carcinoma Jpn J Cancer Res 93 2002 1201
18. H. Takayama, T. Takakuwa, Z. Dong, N. Nonomura, A. Okuyama, S. Nagata Fas gene mutations in prostatic intraepithelial neoplasia and concurrent carcinoma analysis of laser capture microdissected specimens Lab Invest 81 2001 283
19. M.S. Shin, H.S. Kim, S.H. Lee, W.S. Park, S.Y. Kim, J.Y. Park Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers Cancer Res 61 2001 4942
20. J. Adams, D. Cuthbert-Heavens, S. Bass, M.A. Knowles Infrequent mutation of TRAIL receptor 2 (TRAIL-R2/DR5) in transitional cell carcinoma of the bladder with 8p21 loss of heterozygosity Cancer Lett 220 2005 137
21. F.G. Perabo, S. Kamp, D. Schmidt, H. Lindner, G. Steiner, R.H. Mattes Bladder cancer cells acquire competent mechanisms to escape Fas-mediated apoptosis and immune surveillance in the course of malignant transformation Br J Cancer 84 2001 1330
22. S.H. Lee, J.Y. Lee, W.S. Park, S.Y. Kim, J.J. Jang, N.J. Yoo Transitional cell carcinoma expresses high levels of Fas ligand in vivo BJU Int 83 1999 698
23. D. Chopin, R. Barei-Moniri, P. Maille, M.A. Frere-Belda, B. Muscatelli-Groux, N. Merendino Human urinary bladder transitional cell carcinomas acquire the functional Fas ligand during tumor progression Am J Pathol 162 2003 1139
24. Y.A. Yeh, J.W. Wang, C.Y. Fan, S.L. MacLeod, K. Fan Expression of fas ligand in metastatic prostatic carcinoma suggestive of possible clonal expansion of subpopulation with metastatic potential Diagn Mol Pathol 10 2001 236
25. Y. Furuya, O. Nagakawa, H. Fuse Prognostic significance of serum soluble Fas level and its change during regression and progression of advanced prostate cancer Endocr J 50 2003 629
26. M. Kimura, Y. Tomita, T. Imai, T. Saito, A. Katagiri, T. Tanikawa Significance of serum-soluble CD95 (Fas/APO-1) on prognosis in renal cell cancer patients Br J Cancer 80 1999 1648
27. F.G. Perabo, R.H. Mattes, A. Wirger, G. Steiner, S. Kamp, D. Schmidt Soluble Fas and Fas-ligand in bladder cancer in vitro and in vivo Urol Oncol 6 2001 163
28. Y. Mizutani, H. Matsubara, K. Yamamoto, L.Y. Nan, K. Mikami, K. Okihara Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma Cancer 101 2004 1794
29. C.L. Eaton, J.M. Wells, I. Holen, P.I. Croucher, F.C. Hamdy Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer Prostate 59 2004 304
30. E. Corey, L.G. Brown, J.A. Kiefer, J.E. Quinn, T.E. Pitts, J.M. Blair Osteoprotegerin in prostate cancer bone metastasis Cancer Res 65 2005 1710
31. P. Korkolopoulou, A. Goudopoulou, G. Voutsinas, E. Thomas-Tsagli, P. Kapralos, E. Patsouris c-FLIP expression in bladder urothelial carcinomas its role in resistance to Fas-mediated apoptosis and clinicopathologic correlations Urology 63 2004 1198
32. G. Jonsson, S. Paulie, A. Grandien High level of cFLIP correlates with resistance to death receptor-induced apoptosis in bladder carcinoma cells Anticancer Res 23 2003 1213
33. X. Zhang, T.G. Jin, H. Yang, W.C. DeWolf, R. Khosravi-Far, A.F. Olumi Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer Cancer Res 64 2004 7086
34. C. Conticello, F. Pedini, A. Zeuner, M. Patti, M. Zerilli, G. Stassi IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins J Immunol 172 2004 5467
35. U. Ramp, T. Krieg, E. Caliskan, C. Mahotka, T. Ebert, R. Willers XIAP expression is an independent prognostic marker in clear-cell renal carcinomas Hum Pathol 35 2004 1022
36. S.F. Shariat, R. Casella, S.M. Khoddami, G. Hernandez, T. Sulser, T.C. Gasser Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer J Urol 171 2004 626
37. M. Krajewska, S. Krajewski, S. Banares, X. Huang, B. Turner, L. Bubendorf Elevated expression of inhibitor of apoptosis proteins in prostate cancer Clin Cancer Res 9 2003 4914
38. G. Jonsson, S. Paulie, A. Grandien cIAP-2 block apoptotic events in bladder cancer cells Anticancer Res 23 2003 3311
39. S.H. Glick, L.P. Howell, R.W. Devere White Relationship of p53 and Bcl-2 to prognosis in muscle-invasive transitional cell carcinoma of the bladder J Urol 155 1996 1754
40. I.U. Ali, L.M. Schriml, M. Dean Mutational spectra of PTEN/MMAC1 gene a tumor suppressor with lipid phosphatase activity J Natl Cancer Inst 91 1999 1922
41. K.M. Kim, Y.J. Lee Amiloride augments TRAIL-induced apoptotic death by inhibiting phosphorylation of kinases and phosphatases associated with the P13K-Akt pathway Oncogene 24 2005 355
42. O. Micheau, E. Solary, A. Hammann, F. Martin, M.T. Dimanche-Boitrel Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity J Natl Cancer Inst 89 1997 783
43. R. Yu, S. Mandlekar, S. Ruben, J. Ni, A.N. Kong Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in androgen-independent prostate cancer cells Cancer Res 60 2000 2384
44. A. Ashkenazi, R.C. Pai, S. Fong, S. Leung, D.A. Lawrence, S.A. Marsters Safety and antitumor activity of recombinant soluble Apo2 ligand J Clin Invest 104 1999 155
45. H. Yagita, K. Takeda, Y. Hayakawa, M.J. Smyth, K. Okumura TRAIL and its receptors as targets for cancer therapy Cancer Sci 95 2004 777
46. S. Sudarshan, D.H. Holman, M.L. Hyer, C. Voelkel-Johnson, J.Y. Dong, J.S. Norris In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer Cancer Gene Ther 12 2005 12
47. A.T. Ludwig, J.M. Moore, Y. Luo, X. Chen, N.A. Saltsgaver, M.A. O'Donnell Tumor necrosis factor-related apoptosis-inducing ligand a novel mechanism for Bacillus Calmette-Guerin-induced antitumor activity Cancer Res 64 2004 3386
48. M.L. Hyer, S. Sudarshan, Y. Kim, J.C. Reed, J.Y. Dong, D.A. Schwartz Downregulation of c-FLIP sensitizes DU145 prostate cancer cells to Fas-mediated apoptosis Cancer Biol Ther 1 2002 401
49. K. McEleny, R. Coffey, C. Morrissey, K. Williamson, U. Zangemeister-Wittke, J.M. Fitzpatrick An antisense oligonucleotide to cIAP-1 sensitizes prostate cancer cells to fas and TNFalpha mediated apoptosis Prostate 59 2004 419
50. A. Amantana, C.A. London, P.L. Iversen, G.R. Devi X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells Mol Cancer Ther 3 2004 699
51. J.D. Kelly, J. Dai, P. Eschwege, J.S. Goldberg, B.P. Duggan, K.E. Williamson Downregulation of Bcl-2 sensitises interferon-resistant renal cancer cells to Fas Br J Cancer 91 2004 164
52. S. Fuessel, B. Kueppers, S. Ning, M. Kotzsch, K. Kraemer, U. Schmidt Systematic in vitro evaluation of survivin directed antisense oligodeoxynucleotides in bladder cancer cells J Urol 171 2004 2471
53. A.D. Brooks, T.J. Sayers Reduction of the antiapoptotic protein cFLIP enhances the susceptibility of human renal cancer cells to TRAIL apoptosis Cancer Immunol Immunother 54 2005 499
54. A.D. Schimmer Inhibitor of apoptosis proteins translating basic knowledge into clinical practice Cancer Res 64 2004 7183
55. L. Pukac, P. Kanakaraj, R. Humphreys, R. Alderson, M. Bloom, C. Sung HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo Br J Cancer 92 2005 1430
56. C. Voelkel-Johnson An antibody against DR4 (TRAIL-R1) in combination with doxorubicin selectively kills malignant but not normal prostate cells Cancer Biol Ther 2 2003 283
57. T.S. Griffith, J.M. Fialkov, D.L. Scott, T. Azuhata, R.D. Williams, N.R. Wall Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma Cancer Res 62 2002 3093
58. M. Nikrad, T. Johnson, H. Puthalalath, L. Coultas, J. Adams, A.S. Kraft The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim Mol Cancer Ther 4 2005 443
59. Y. Mizutani, Y. Okada, O. Yoshida, M. Fukumoto, B. Bonavida Doxorubicin sensitizes human bladder carcinoma cells to Fas-mediated cytotoxicity Cancer 79 1997 1180
60. M.L. Hyer, S. Sudarshan, D.A. Schwartz, Y. Hannun, J.Y. Dong, J.S. Norris Quantification and characterization of the bystander effect in prostate cancer cells following adenovirus-mediated FasL expression Cancer Gene Ther 10 2003 330